Optimizing the anticoagulation therapy is of pivotal importance in patients with a malignant
tumor, as venous thromboembolism (VTE) has become the second-leading cause of death …

Venous thromboembolism (VTE) is a common complication of cancer and has a significant
impact on morbidity and mortality in patients with malignancies. Low molecular weight …

Patients diagnosed with cancer often experience an abnormal occurrence of venous
thromboembolism (VTE) and its related complications. In order to evaluate the safety and …

Background Low‐molecular‐weight‐heparins (LMWHs) have been established for the
treatment of cancer‐associated venous thromboembolism (VTE). Recently published …

Venous thromboembolism (VTE) complicates the clinical course of approximately 5–10% of
all cancer patients. Anticoagulation of the cancer patient often presents unique challenges …

Venous thromboembolism (VTE) is a common cause of morbidity and mortality in patients
with cancer. Compared with the general population, cancer patients with VTE have higher …

The efficacy and safety of direct oral anticoagulants (DOACs) versus low-molecular-weight
heparin (LMWH) are still debated in the treatment of patients with cancer, and the optimal …

Abstract Changes in the hemostatic system and chronic hemostatic activation are frequently
observed in patients with cancer, even in the absence of venous thromboembolism (VTE) …

Venous thromboembolism (VTE) is associated with increased morbidity and mortality,
decreased quality of life, and higher economic burden in patients with cancer. Currently, the …

Purpose The standard of care for the treatment of cancer-related venous thromboembolism
(VTE) is a low molecular weight heparin (LMWH) formulation. The recent development of …